Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

By sjmartinez • April 27, 2023

Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2023 Apr 26. doi: 10.1002/art.42510. Epub ahead of print. PMID: 37098795.

Tags: Publications, Rheumatology

Forearm BMD predicts fracture independently of FRAX

Kanis JA, Johansson H, Harvey NC, Lorentzon M, Cauley JA, Crandall CJ, Huisman M, Khosla S, Kwok T, Mellström D, Orwoll ES, van Schoor NM,[...]

Ethical Challenges of Extracorporeal Membrane Oxygenation: Enhanced Recovery After Surgery Cardiac Society Consensus on Key Issues and Practical Recommendations

Griffee MJ, Kirsch RE, Rubin J, Peeler A, Hayanga JW, Chatterjee S, Dorsey D, Emeruwa IO, Goodwin ML, Rubin EB, Kim BS, Grant MC, Zaaqoq[...]

Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease

Sandhu AT, Furst A, Rodriguez F, Kalwani N, Maron D, Nallamshetty S, Din N, Zitko K, Khachatourian K, Skaar JR, Tonnu-Mihara I. Systemic Inflammation and[...]